Nestlé Health Science has signed an exclusive agreement outside USA and Canada to support the possible commercialization, in the future, of the Microbiome-targeting treatments developed by beings Therapeutics. In this sense, Nestlé Health Science aims to treat inflammatory bowel disease (IBD), as well as infections from Clostridium difficile (C. difficile). It is an intestinal infection caused by the bacterium C. difficile which, in some cases, can be fatal.
To carry out this treatment, the Swiss firm will invest over 120 million Swiss francs to support “ecobioticos” drugs of beings, a new class of biological drugs based on micro-organisms. These drugs Act on the Microbiome, i.e. about 100 trillions of microorganisms that inhabit the human body.
Scientific studies point increasingly to the relationship that exists between the Microbiome ill or unbalanced and a series of diseases, including IBD and infections due to C. difficile. This type of infections are more frequent among adults 65 and older, as well as in immunocompromised patients who have been treated with antibiotics broad-spectrum underlying infections.
In Europe, the number of cases treated by 2015 was 308.000 patients, a number believed that it will rise to 344,000 patients in the year 2025. According to specialists, the CDI may contribute to causing a 40% of the deaths, in the three months after the diagnosis, so it is an important public health issue.